Cholesteryl Ester Transfer Protein in Patients with Rheumatoid Arthritis

Ferraz-Amaro, Iván; González-Gay, Miguel Á.; García-Dopico, José A.; Dı́az-González, Federico

doi:10.3899/jrheum.121507

Cited by 23 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, in active RA patients, besides inflammation, fat mass distribution can be contributing to elevated CETP activity. In contrast with our results, FerrazAmaro et al [50] have previously reported low CETP activity in RA patients under treatment with glucocorticoids. In parallel, the authors have also documented elevated HDL-C levels, an observation that differs from our results and from data earlier reported by others [5].…”

Section: Discussioncontrasting

confidence: 86%

Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis

et al. 2016

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 86%

Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis

et al. 2016

View full text Add to dashboard Cite

“…In addition, the fact that SSc display lower levels of total cholesterol and higher triglycerides than controls has also been previously described [10,11], although in smaller cohorts that lacked multivariate analysis. The lipid pro le differences between patients and controls found in our study are in accordance with the 'lipid paradox' [15] described in other in ammatory diseases like RA [6,16,17] or SLE [18]. This means that untreated in ammatory diseases are associated with lower levels of total cholesterol and LDL-cholesterol, and it is believed that this may stem from the lipid-lowering effects of systemic in ammation.…”

Section: Discussionsupporting

confidence: 90%

HDL-Cholesterol Efflux Capacity and Lipid Profile in Patients With Systemic Sclerosis

Ferraz‐Amaro

Delgado-Frías

Hernández-Hernández

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Objective. It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients respect to controls and whether these changes were associated with disease-related data.Methods. Cross-sectional study encompassed 188 individuals: 73 SSc patients and 115 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SSc-related data could explain such differences. Results. The multivariate analysis adjusted for demographic characteristics, cardiovascular risk factors and lipid-related molecules showed that total cholesterol (beta coefficient: -22 [95%CI -37- -7], p=0.004), triglycerides (beta coefficient: 24 [95%CI 2-47], p=0.033), lipoprotein A (beta coefficient: 22 [95%CI 2-43], p=0.033) and CEC (beta coefficient: -6 [95%CI -10- -2]%,p=0.002) were significantly differences between patients and controls. Skin thickness, as assessed by modified Rodnan skin score, was independently associated with a lower CEC (beta coefficient: -0.21 [95%CI -0.37- -0.05]%, p=0.011) after multivariable adjustment.Conclusion: SSc patients show an abnormal lipid profile respect to controls including CEC, a finding that could be involved in the increased cardiovascular burden suffered by these patients. Skin thickness is independent and inversely associated with CEC in SSc patients.

show abstract

“…Lipid profile differences between patients and controls found in our report are in accordance with the 'lipid paradox' (32) described in other inflammatory diseases such as rheumatoid arthritis (17,33,34) or systemic lupus erythematosus (35). This means that individuals with untreated inflammatory diseases or those with these conditions who have high disease activity exhibit lower levels of total cholesterol and LDL cholesterol, and it is believed that this may be due to the lipid-lowering effects of systemic inflammation.…”

Section: Discussionsupporting

confidence: 90%

Proprotein Convertase Subtilisin/Kexin Type 9 in the Inflammation-Related Dyslipidemia of Patients with Axial Spondyloarthritis is Related to Disease Activity.

Ld¹,

Quevedo-Abeledo²,

Ad³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation and that has been linked to cardiovascular risk. The purpose of the present study was to examine whether PCSK9 levels are related to both abnormalities in the lipid profile and the development of severe atherosclerosis that often occurs in patients with axial spondyloarthritis (axSpA). Methods: Cross-sectional study that encompassed 545 individuals; 299 patients with axSpA and 246 statin use-matched controls. PCSK9, lipoproteins serum concentrations and standard lipid profiles were analyzed in patients and controls. Carotid intima-media thickness (cIMT) and carotid plaques were assessed in patients. A multivariable analysis, adjusted for standard cardiovascular risk factors, was performed to evaluate the influence of PCSK9 on axSpA related dyslipidemia and subclinical carotid atherosclerosis.Results: Most lipid panel parameters (total cholesterol, HDL- and LDL-cholesterol, lipoprotein (a) and apoliprotein A1) were significantly lower in axSpA patients than controls. PCSK9 serum levels (beta coef. -44 [95%CI -60- -27] ng/dl, p=0.000) were also downregulated in axSpA patients after fully multivariate adjustment, including other lipid profile-related molecules modifications that the disease generates. Unadjusted higher levels of PCSK9 were associated with carotid plaque in axSpA patients (beta coef. 27 [95%CI 9-45], p=0.003). ASDAS-CRP was found to be independently and significantly related to PCSK9 (beta coef. 10 [95%CI 1-18] ng/dl, p=0.023) after analyzing fully adjusted models that took age, sex, and the rest of lipid profile molecules into account. Whereas patients taking prednisone showed higher serum levels of PCSK9 (55 [95%CI 24-8]) ng/ml, p=0.001), those under anti-TNF alpha therapies exhibited lower levels (beta coef. -26 [95%CI -43- -9], p=0.003).Conclusion: PCSK9 is downregulated in patients with axSpA. Disease activity is positive and significantly related to PSCK9. Anti-TNF-therapy yields reduction in PCSK9 serum levels.

show abstract

Cholesteryl Ester Transfer Protein in Patients with Rheumatoid Arthritis

Abstract: CETP is downregulated in patients with RA who are taking glucocorticoids. Low CETP activity is associated with an increased level of cardiovascular risk in patients with RA.

Cited by 23 publications

References 40 publications

Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis

Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis

HDL-Cholesterol Efflux Capacity and Lipid Profile in Patients With Systemic Sclerosis

Proprotein Convertase Subtilisin/Kexin Type 9 in the Inflammation-Related Dyslipidemia of Patients with Axial Spondyloarthritis is Related to Disease Activity.

Contact Info

Product

Resources

About